Please use this identifier to cite or link to this item:
Title: Nilotinib does not alter the secretory functions of carotid artery endothelial cells in a prothrombotic or antithrombotic fashion
Authors: Katgı, Abdullah
Sevindik, Ömer Gökmen
Adan Gökbulut, Aysun
Özsan, Güner Hayri
Yüksel, Faize
Solmaz, Şerife Medeni
Alacacıoğlu, İnci
Özcan, Mehmet Ali
Demirkan, Fatih
Baran, Yusuf
Pişkin, Özden
Keywords: Carotid artery
Cell viability
Endothelial cells
Issue Date: Oct-2015
Publisher: SAGE Publications Inc.
Source: Katgı, A., Sevindik, Ö. G., Adan Gökbulut, A., Özsan, G. H., Yüksel, F., Solmaz, Ş. M., Alacacıoğlu, İ., Özcan, M. A., Demirkan, F., Baran, Y., and Pişkin, Ö. (2015). Nilotinib does not alter the secretory functions of carotid artery endothelial cells in a prothrombotic or antithrombotic fashion. Clinical and Applied Thrombosis/Hemostasis, 21(7), 678-683. doi:10.1177/1076029614550817
Abstract: Background: There have been concerns about the possible prothrombotic effects of nilotinib, especially in patients having cardiovascular risk factors. The potential mechanism behind the increased risk of thromboembolic events is still not clear. Objectives: In this study, we aimed to evaluate possible harmful effects of nilotinib on endothelial cells. To this aim, we examined proliferative capacity and secretory functions of healthy human carotid artery endothelial cells (HCtAECs) in response to nilotinib. Methods: 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation method was used to determine antiproliferative effects of nilotinib on HCtAECs. The HCtAECs were incubated with 5, 10, and 100 nmol/L doses of nilotinib for 72 hours. Then, in order to assess the endothelial function, levels of nitric oxide (NO), von Willebrand factor (vWF), tissue plasminogen activator, plasminogen activator inhibitor 1 (PAI-1), and endothelin 1 (ET-1) were evaluated using enzyme-linked immunosorbent assay from tissue culture supernatants. Results: There were slight but statistically significant decreases in cell proliferation in response to nilotinib. Nilotinib increased the secretion of t-PA, PAI-1, and vWF in a dose-dependent manner when compared with the untreated control group. The ET-1 secretion was lower in 5 nmol/L and higher in 10 and 100 nmol/L nilotinib-treated cells as compared to untreated cells. Regarding NO secretion, lower levels were observed in 5 and 10 nmol/L, and higher levels were detected in 100 nmol/L nilotinib-treated cells as compared to untreated control group cells. Conclusion: Considering the results obtained in our study, nilotinib does not affect the functions of endothelial cells either in a prothrombotic or an antithrombotic fashion, despite a dose-dependent decline in cell viability.
ISSN: 1076-0296
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File Description SizeFormat 
5683.pdfMakale254.8 kBAdobe PDFThumbnail
Show full item record

CORE Recommender

Google ScholarTM



Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.